Last reviewed · How we verify

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

NCT03139981 PHASE1 COMPLETED

This is a dose escalation study to test the safety, tolerability and preliminary efficacy of ASN002 in people with moderate to severe atopic dermatitis (AD).

Details

Lead sponsorAsana BioSciences
PhasePHASE1
StatusCOMPLETED
Enrolment36
Start dateWed Apr 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
CompletionTue Dec 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Interventions

Countries

Canada, United States